Polyrizon

Polyrizon EBITDA Growth YoY

The Year-over-Year EBITDA Growth of Polyrizon (PLRZ) as of Oct 24, 2026 is -317.18 %. In the previous year, Year-over-Year EBITDA Growth was -124.57 % — a change of 154.63% (lower).

EBITDA Growth YoY

-317.18 %

YoY

154.63%

Last updated:

Year-over-Year EBITDA Growth of Polyrizon is 2025 -317.18 % . Year-over-Year EBITDA Growth of Polyrizon was 2024 -124.57 % . It decreases by 154.63% lower compared to the previous year.

The Polyrizon EBITDA Growth YoY history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Growth YoY
Date
EBITDA Growth YoY
Jan 1, 2021
-876.39 USD
Jan 1, 2022
-27.31 USD
Jan 1, 2023
29.05 USD
Jan 1, 2024
-124.57 USD
Jan 1, 2025
-317.18 USD
The Polyrizon EBITDA Growth YoY history
YEAREBITDA Growth YoYYoY
-317.18 %+154.63%
-124.57 %-528.80%
29.05 %-206.37%
-27.31 %-96.88%
-876.39 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Polyrizon Stock analysis

What does Polyrizon do? Polyrizon Ltd develops medical device hydrogels delivered as nasal sprays that form a thin barrier in the nasal cavity to block viruses and allergens. The company specializes in creating a biological mask using naturally occurring building blocks, focusing on both product development and commercialization. Medical specialists and researchers collaborate with Polyrizon Ltd to advance their intranasal solutions. The firm's primary revenue comes from the development and commercialization of its nasal spray hydrogel products. These products target healthcare providers and consumers seeking protection against viral and allergen exposure. By forming a shield containment barrier, Polyrizon Ltd offers a solution that complements existing health measures without requiring additional equipment. Polyrizon Ltd's business model centers on the creation of a unique nasal barrier technology. The company leverages its focus on intranasal delivery to address market needs for non-invasive protection. Its collaboration with medical specialists ensures that its products meet clinical standards and user requirements. Polyrizon is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Polyrizon stock

Year-over-Year EBITDA Growth of Polyrizon is -317.18 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year EBITDA Growth Polyrizon since 2006 – with annual values, charts, and detailed analysis.

EBITDA growth measures the percentage change in EBITDA compared to the prior year. It shows changes in operating cash earnings before capital structure effects.

To evaluate Year-over-Year EBITDA Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBITDA Growth.

Year-over-Year EBITDA Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBITDA Growth's Polyrizon historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Polyrizon

All Key Metrics — Polyrizon